Gene amplification, a common mechanism for oncogene activation in cancer, has been used as a tag for the identification of novel oncogenes. DNA amplification is frequently observed in head and neck squamous cell carcinoma (HNSCC) and potential oncogenes have already been reported. We applied restriction landmark genome scanning (RLGS) to study gene amplifications and low-level copy number changes in HNSCC in order to locate previously uncharacterized regions with copy number gains in primary tumor samples. A total of 63 enhanced RLGS fragments, indicative of DNA copy number changes, including gains of single alleles, were scored. Enhanced sequences were identified from 33 different chromosomal regions including those previously reported (e.g. 3q26.3 and 11q13.3) as well as novel regions (e.g. 3q29, 8q13.1, 8q22.3, 9q32, 10q24.32, 14q32.32, 17q25.1 and 20q13.33). Furthermore, our data suggest that amplicons 11q13.3 and 3q26.3-q29 may be divided into possibly two and three independent amplicons, respectively, an observation supported by published microarray expression data.
Introduction
Gain of DNA copy number or DNA amplifications are common genetic alterations found in most cancers (Schimke, 1990) . Subchromosomal DNA amplification results in extra copies of specific regions, potentially containing proto-oncogenes. DNA amplification often results in overexpression of a target gene located within the amplified region but also in overexpression of coamplified genes (Schwab, 1999) . Overexpression of a proto-oncogene subsequently results in neoplastic transformation and provides a growth advantage either by providing resistance to apoptotic stimuli (Lyons and Clarke, 1997) , or by promoting accelerated cell growth (Neve et al., 2001) . Amplification and overexpression of proto-oncogenes is often (but not always) an early event in tumorigenesis (Schwab and Amler, 1990 ) and thus can be used as diagnostic marker for early detection of tumor cells, or to predict outcome of disease progression. Furthermore, activated oncogenes provide potential targets for cancer therapies (Bitzer et al., 2003) .
In the past, gene amplification in head and neck squamous cell carcinoma (HNSCC) has been observed using comparative genomic hybridization (CGH) (Fan et al., 2000; Huang et al., 2002) , fluorescent in situ hybridization (FISH) (Matsumura et al., 2000; Riazimand et al., 2002) and recently array-based CGH (Redon et al., 2002; Garnis et al., 2004) . The most frequent amplifications in HNSCC include copy number gains of chromosomes 3q26 (Singh et al., 2001; Huang et al., 2002; Estilo et al., 2003) , 8q24 (Huang et al., 2002; Singh et al., 2001 ) and 11q13 (Fan et al., 2000) . Protooncogenes in these regions include phosphatidylinositol 3-kinase (PI-3K) catalytic alpha subunit (PIK3CA), cmyc (MYCC), and cyclin D1 (CCND1), respectively (Estilo et al., 2003; Fan et al., 2000; Speicher et al., 1995) . Many other less-frequent amplification events have been reported, but candidate proto-oncogenes remain undiscovered.
Here we utilized restriction landmark genomic scanning (RLGS) as a tool for comprehensive identification of DNA copy number changes in HNSCC. RLGS allows the detection of even low levels of DNA copy number changes and may help to pinpoint smaller amplicons that have been missed by other techniques. The intensities of RLGS fragments correlate directly with DNA copy numbers, allowing the reproducible detection of even two-fold increases (Hirotsune et al., 1992) or the gain of a single chromosome. We report the identification of numerous novel regions demonstrating DNA copy number changes in HNSCC and show the existence of several independent regions displaying gain of copy numbers on 3q26.3 and 11q13.3.
Results and discussion
A genome-wide search for DNA copy number gains in HNSCC RLGS allows the detection of low-level DNA copy number changes and has been used in the past to identify several proto-oncogenes, including the cyclindependent kinase, CDK6, in glioblastomas (Costello et al., 1997) , MYCL in ovarian carcinomas (Wu et al., 2003) , and inhibitors of apoptosis, cIAP1 and cIAP2, in lung carcinomas (Dai et al., 2003) . Here we used RLGS analysis on paired primary tumor and normal adjacent tissues from HNSCC patient samples for the identification of copy number gains. A total of 41 pairs of NotIEcoRV-HinfI RLGS profiles were generated for this study. RLGS gels were analysed for enhanced fragments only. Two types of enhancements were observed. Type 1 enhancements represent those RLGS fragments that were present in both normal and tumor gels; however, the relative intensity of the tumor fragment was increased. Type 2 enhancements represent those RLGS fragments that existed exclusively in tumor tissues and thus were not found in the RLGS gels of normal tissues (see Figure 1a and b for examples). Table 1 lists 63 enhanced and cloned NotI-EcoRV RLGS fragments that have been identified in HNSCC samples. Out of 63 identified sequences, 11 were located within chromosomal region 3q26.1-3q27.1, a region which represents the most frequently amplified region in HNSCC (Huang et al., 2002; Estilo et al., 2003) . Four sequences were identified from 11q13.3 and one from 8q24.21, representing the locations of CCND1 and MYCC. In all, novel sequences were detected. Interestingly, some of these regions (1q41, 7p22, 8p11.23, 8q13.1, 8q22.3, 10q21.3, 10q24.32, 19q13.1, 20p11 .23) have been described as amplified sequences in other human malignancies (Bruch et al., 1998; Curtis et al., 1998; Du Plessis et al., 1999; Larramendy et al., 2000; Pimkhaokham et al., 2000; Tang et al., 2002; Dai et al., 2003; Lukasova et al., 2004; Rao et al., 2004) . The RLGS data does not allow us to discriminate between DNA copy number gains that have integrated at the location of the original sequence or extra DNA localized in extrachromosomal double minutes. However, whole chromosome events are detectable in RLGS profiles by increased intensities in all RLGS fragments localized on the duplicated chromosome.
Confirmation of DNA amplification by Southern blotting
To confirm enhancements detected by RLGS, we used Southern blot analysis on 17 RLGS sequences ( Figures  2 and 4b ). Southern blot band intensities of the candidate amplified sequences were compared to the intensity of a nonamplified control fragment, located on chromosome 21q22.3, in order to normalize the relative intensities. The control sequence represented an unchanged RLGS fragment (2E12) located outside of regions with copy number changes (as confirmed by RLGS spot intensities). A 1.4-fold or greater increase in relative intensity in the tumor DNA was considered to represent DNA copy number gain. Five or six pairs of patient samples were probed with the test fragments. We found concordance of the RLGS data with Southern blot data in 69 out of total 77 events (90%). The eight discrepancies were fragments either not scored by RLGS (n ¼ 7), or scored by RLGS but not confirmed in Southern (n ¼ 1). Furthermore, Southern blot results showed that events over two-fold enhancement were not common, with the exception of copy number gains of sequences from the 3q26.1-q29 region (see Figure 4b , PT91T for example). The discordant cases are most likely explained by technical limitations owing to the low level of amplification being at the threshold of experimental error. Interestingly, RLGS fragment 2E52, which was reduced in tumor sample PT173, showed also reduction to 0.42-fold intensity as measured by Southern blot analysis, further supporting the high concordance between RLGS results and quantitative Southern blot results. The most frequently amplified RLGS fragment was 3FX, which was observed in 71% (40 in 56) of all cancerous tissue RLGS profiles, but never in normal adjacent tissue profiles ( Figure 1b ). The sequence of this type 2 enhancement had previously been reported in lung cancer and neuroblastoma, and A white square indicates no change in copy number, gray indicates an increase from 1.5-to 4-fold and black indicates an enhancement >4-fold. A (?) indicates that the particular RLGS fragment was not analysable on the gel and a (R) indicates a reduction of fragment intensity.
DNA amplification in HNSCC
M Lin et al represents a human tandem repetitive element (accession number L09552) on 8q21.2 (Thoraval et al., 1996; Dai et al., 2003) . Southern blot data confirmed that the appearance of RLGS fragment 3FX is the consequence of loss of DNA methylation in NotI sites located in a normally methylated repeat sequence (L09552) (data not shown).
Novel DNA amplification events detected by RLGS in HNSCC Table 1 summarizes the DNA copy number gains in HNSCC obtained by RLGS analysis, as well as their chromosomal locations. These copy number changes were compared with DNA amplification events currently described in the literature ( Table 2 ). The RLGS findings were highly consistent with previous reports on the most frequently amplified regions. Gains of 3q26-27, 7p, 8q24, 11q13, 12p, 17q, 18p, 20p, and 20q have been documented in the literature by RLGS and other detection methods. In addition, RLGS analysis identified several novel sequences on chromosome 2q21.1
.1 (n ¼ 6) and 17q25.1 (n ¼ 5).
Contiguous RLGS fragments can be used to determine amplicon structure RLGS fragments colocalizing within a short chromosomal region and showing similar levels of enhancement were likely amplified together (Dai et al., 2003) . Figure 3 represents RLGS fragments from chromosome 11q13.3, a well-documented amplicon in HNSCC. Four RLGS fragments from 11q13.3 (2F51, 6FX, 2F63 and 6G27) were found located within a B755 kbp region. Sequence analysis indicated that RLGS fragments 2F51 and 6FX represent a single NotI-NotI restriction fragment localized in the promoter region of CCND1. Furthermore, 6G27 represents a NotI site found in the promoter of EMS1. Both CCND1 and EMS1 are HNSCC protooncogenes described in previous studies (Rodrigo et al., 2000; Arai et al., 2003) . Among 41 patient samples, both 2F51 and 6FX always showed the same levels of enhancement (enhanced in 10 cases; 24%), while 2F63 was observed in nine cases (22%), and 6G27 was enhanced in 11 cases (27%). Most importantly, in the majority of samples, all four RLGS fragments were enhanced to the same level (see Figure 3 , PT29 for example). In PT40, 2F51/6FX (CCND1) and 6G27 (EMS1) were enhanced, but not 2F63, which is physically mapped between these genes in the genome, (Figure 3 ) suggesting the presence of two potential core amplicons. Enhancement of 6G27 (EMS1), but not 2F51/6FX (CCND1) or 2F63, was seen in PT16 ( Figure 3 ). We have not found samples showing 2F51/ 6FX (CCND1) amplification alone. These data indicated that CCND1 amplification is not necessarily associated with EMS1 amplification and thus supports earlier work by Rodrigo et al. (2000) indicating that EMS1 and CCND1 amplification could occur separately. Interestingly, the authors found that not CCND1 amplification but EMS1 predicts early recurrence and reduced survival in HNSCC. Therefore, the prognostic significance previously attributed to CCND1 amplification may be attributable to its colocalization with EMS1 on the same amplicon (Rodrigo et al., 2000) .
Subclassification of amplicons on chromosome 3q26.3-q29
We have identified 19 RLGS markers spanning chromosomal region 3q26.1-q29 (Figure 4a ), which includes the most frequently reported amplification in HNSCC (Table 1 region 3q ). The two most frequent copy number gains were scored for RLGS fragments 3D17 (21/41, 51%) and 3D21 (17/41, 41%), both mapping to 3q26.32. Interestingly, these sequences were located in a region that includes PIK3CA, a known proto-oncogene, not only in HNSCC (Estilo et al., 2003) but also in cervical (Ma et al., 2000) , ovarian, breast (Campbell et al., 2004) and lung squamous cell carcinomas (Racz et al., 1999) . Numerous patient samples demonstrated consecutive DNA copy number gain in several markers in this region, suggesting that the whole 3q26.1-3q29 region was amplified as a single amplicon (e.g. PT12, PT24). However, in other patients (PT110, PT174 and PT175) only the 3q29 fragments 3q27.1 not the 3q26.32 or fragments showed enhancement, suggesting the presence of a smaller amplicon. This assumption was further supported by the finding of two distinct regions with copy number gains in PT2. The first region was localized on 3q26.32 (3D17 and 3D21) and the second region on 3q29 (5D03, 2C38 and 4F31). Two regions were separated by eight RLGS sequences that did not demonstrate enhancement by RLGS and/or Southern (5E06 to 4B25) in PT2. In addition, there was evidence that chromosomal region 3q26.32-q27.1 may represent two separate amplicons. Patients PT2 and PT71 displayed enhancement of 3q26.32 fragments (3D17 and 3D21) without amplification of a further telomeric marker in the 3q27.1 region (see Table 1 and Figure 4a) . However, PT16, PT45, PT50 and PT56 demonstrated only amplification of the 3q27.1 marker. The amplification data suggest the presence of at least three separate amplicons on chromosome 3q: region 1 on 3q26.32 encompasses the known oncogene PIK3CA; region 2 localized on 3q27.1; and region 3 on 3q29. The RLGS data were validated by Southern blot analysis using RLGS sequences from different regions on patient samples and matched normal controls (Figure 4b ). PT91 and PT114 showed DNA amplification in HNSCC M Lin et al consecutive amplifications of regions 1, 2 and 3, whereas PT167 showed only amplification in region 3. PT99 showed amplification of markers in region 1, 2 and 3, separated by nonamplified fragments (1G20, 5E06, 5F39
and 4E12). PT126 did not show any enhancement in the sequences tested by Southern analysis. However, RLGS indicated copy number gain in fragments 2E46 and 3E46. In order to find further support for copy number freeze. Arrows and arrowheads are used to point out these spots. Three patient sample pairs are used to demonstrate segmental amplifications. In PT91T, all fragments are enhanced. In PT16T, only 3E24 (3q27.1) and 3F38 (3q29) are enhanced. In PT71T, only 3D17 and 3D21 (3q26.32) are enhanced. (b) Results of 10 RLGS fragments on chromosome 3q26.1-q29 in five patient sample pairs. NotI/EcoRV-digested genomic DNAs of five patient pairs were used. RLGS fragment, 2E12, serves as the internal control. Relative increases are summarized in the right panel. Intensities over 1.4 are considered amplification. Dark gray indicates enhancement on actual RLGS gels, and light gray indicates that the RLGS fragments were not analysable in the particular gels.
gains on 3q29, we evaluated gene expression data in HNSCC published by Ginos et al. (2004) for genes on 3q29 and found frequent overexpression of several genes, including mucin 4 (MUC4), a gene found to be amplified overexpressed in pancreatic cancers (Swartz et al., 2002) with oncogenic abilities (Singh et al., 2004) . MUC4 mRNA levels were upregulated in at least 35% HNSCC cases. Our data further suggest a potentially independent amplicon on 3q27.1 characterized by RLGS fragments 2F72-3E24. This 345 kbp region includes at least 16 genes. Two of these genes, disheveled 3 (DVL3) and EIF4G1, have been shown to be amplified in hypopharyngeal cancers (Cromer et al., 2004) .
In conclusion, we reported a comprehensive list of copy number gains in HNSCC, including numerous novel sequences that have not been reported for this tumor type. Furthermore, we were able to further subclassify an amplified region on chromosome 3q into three independent amplicons. Future studies will be needed to identify candidate proto-oncogenes within these locations.
Materials and methods

HNSCC cell lines and patient samples
Primary HNSCC, derived from the nasal cavity (n ¼ 2), oral cavity (n ¼ 20), larynx (n ¼ 7), pharynx (n ¼ 7) and undocumented (n ¼ 5) were obtained from the Cooperative Human Tissue Network. Surgery was performed on all patients at The Ohio State University. All normal specimens were harvested from morphologically normal appearing tissue located at least 3 cm from the tumor margin and were used as the normal control tissue for comparisons with the tumor tissues. Histopathological characterization was performed for both normal and primary tumor. Samples were snap frozen in liquid nitrogen and stored at À801C prior to DNA isolation. The study was performed under a protocol approved by the Institutional Review Board of The Ohio State University.
Genomic DNA preparation
The protocol for extraction of genomic DNA from normal adjacent and cancerous tissues has been described previously (Smiraglia et al., 1999) . In brief, frozen tissue samples were crushed and incubated in 15-20 ml lysis buffer in the presence of 100 mg/ml proteinase K at 551C for 1 h or until the buffer becomes homogenous. Two phenol:chloroform:isoamyl alcohol extractions were performed using Phase Lock Gel tubes (Eppendorf, Hamburg, Germany). DNA was dialyzed overnight in 10 mM Tris and RNase-treated for 2 h at 371C. Following ethanol precipitation DNA was stored in TE buffer.
Restriction landmark genomic scanning We followed the published protocol of Dai et al. (2003) . In brief, extracted genomic DNAs were incubated with DNA polymerase I (Boehringer Mannheim, Indianapolis, IN, USA) for blocking the randomly sheared ends. DNA samples were digested with NotI (Promega, Madison, WI, USA) for 2 h and restriction ends were labeled using [a-32 P]dGTP and [a-32 P]dCTP together with Sequenase (Amersham, Piscataway, NJ, USA), followed by an EcoRV (Promega) digestion. The labeled NotI-EcoRV fragments were separated in 0.8% agarose gels. Separated DNA fragments were further digested with HinfI (New England Biolabs, Ipswich, MA, USA), and further separated in a second-dimension 5% polyacrylamide gel. The acrylamide gels were then transferred onto 43 Â 35 cm filter papers, dried, and exposed to the X-ray films (Kodak, New Haven, CT, USA) for 5-10 days.
Analysis of RLGS gel pictures
All shown RLGS fragments were given unique addresses according to the 'RLGS Master Profile'(http://pandora.med.ohio-state.edu/masterRLGS). We compared the intensities of RLGS fragments from tumor tissues to those from normal adjacent tissues from the same individuals. Analyses were performed by CONIME, customized computer software developed by Dr Wenger of Ohio State University (Wenger et al., manuscript in preparation). We used the software to mark any mismatches on intensity, including gain and loss, by automatic and manual picks. These mismatches were further examined by visual inspection of original gels.
RLGS spot cloning RLGS fragments were cloned utilizing the NotI-EcoRV clone libraries (Costello et al., 1997; Smiraglia et al., 1999; Dai et al., 2003) . Alternatively, known NotI-EcoRV fragments from these libraries were used in RLGS mixing gels to identify corresponding RLGS fragments. We used the UCSC Genome Bioinformatics Site (http://www.genome.ucsc.edu) for sequence analysis.
Southern hybridization and quantification
For Southern hybridization, we selected seven pairs of patient samples to digest with NotI and EcoRV at 371C for 2 h. These digested DNA samples were separated in a 0.8% agarose gel at 40 V for 16 h. DNA fragments were transferred onto HyBond membrane and fixed. Probes were designed to hybridize specific NotI-EcoRV fragments identified in the RLGS analysis. We used PCR to generate these probes. Primer sets of probes for RLGS fragments are listed in Table 1 . In all, 10 ng of genomic DNA was amplified by a final volume of 50 ml along with either (a) 10 pmol of the 5 0 and 3 0 primers, 5 ml 10 Â PCR buffer, 1.5 ml 25 mM MgCl 2 , 1 ml 10 mM dNTPs, 0.5 ml Taq polymerase (Invitrogen, Carlsbad, CA, USA) (one asterisk in Table 3 ), or for GC-rich sequences (b) 20 pmol of the 5 0 and 3 0 primers, 5 ml 10 Â special buffer for GC-rich sequence (Herman et al., 1996) , 1.25 ml 25 mM DMSO, 2.5 ml 10 mM dNTPs, and 0.4 ml Taq polymerase (two asterisks in Table 3 ). PCR cycles: 951C for 5 min; 951C for 30 s, individual Tm for 30 s, 721C for 30 s for 35 cycles; 721C for 10 min; preserve at 41C. Probes were end-labeled by [a- 32 P]dCTP with Prime-it II kit (Stratagene, La Jolla, CA, USA). Blots were prehybridized in 0.5 M phosphate buffer containing 7% SDS at 651C for 3 h, along with salmon sperm DNA for blocking. Then the probes were added and incubated for 16 h with rotation. Low-stringency washes (0.2 M phosphate buffer/ 0.1% SDS) were performed at 651C for 30 min, followed by a high-stringency wash (0.02 M phosphate buffer/0.1% SDS) for 15 min at 651C. Labeled blots were sealed and exposed on PhosphorImager screens for five days.
The screens were scanned and quantified to evaluate the fold increase. Our internal control was the intensity of RLGS fragment 2E12, which demonstrated no intensity differences in any of our samples. The equation used to calculate fold increase was (Count Spot /Count 2E12 ) Tumor /(Count Spot / Count 2E12 ) NAT .
HNSCC mRNA expression profiles by microarray mRNA expression profiles were computed from raw HG-U133A probe intensities using RMAExpress with quantile scaling and background correction. RMAExpress program used in analysing microarray data was written by Dr Benjamin M Bolstad (Irizarry et al., 2003) . The CEL files were provided by Patrick M Gaffney and have been described (Ginos et al., 2004) . mRNA expression profiles of 14 normal tissues and 40 HNSCC patient samples were obtained (independent studies from our sample database). The median of the log 2 value of 14 normal tissues' mRNA expression levels was regarded as onefold, so that anything greater than two-fold (log 2 ratio>1) would be considered upregulation. Ninety-five percent of mRNA expression levels in normal tissues are located within two-fold (log 2 value ¼ 1) and 0.5-fold (log 2 value ¼ À1), demonstrating the consistency of normal mRNA levels.
